Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway.
Chen C, Cheng CD, Wu H, Wang ZW, Wang L, Jiang ZR, Wang AL, Hu C, Dong YF, Niu WX, Qi S, Qi ZP, Liu J, Wang WC, Niu CS, Liu QS.
Chen C, et al. Among authors: wang wc, wang al, wang zw, wang l.
Acta Pharmacol Sin. 2021 Jan;42(1):108-114. doi: 10.1038/s41401-020-0418-2. Epub 2020 May 12.
Acta Pharmacol Sin. 2021.
PMID: 32398685
Free PMC article.